IVME Net Debt To E B I T D A from 2010 to 2024
| IVME Stock | USD 0.0001 0.00 0.00% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter (1.56) | Current Value (1.63) | Quarterly Volatility 0.17627689 |
Check In Veritas financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among In Veritas' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 1.4 M, as well as many indicators such as Price To Sales Ratio of 6.63, Days Sales Outstanding of 69.5 or Stock Based Compensation To Revenue of 0.0. IVME financial statements analysis is a perfect complement when working with In Veritas Valuation or Volatility modules.
IVME | Net Debt To E B I T D A |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether In Veritas Medical is a strong investment it is important to analyze In Veritas' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact In Veritas' future performance. For an informed investment choice regarding IVME Stock, refer to the following important reports:Check out the analysis of In Veritas Correlation against competitors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In Veritas. If investors know IVME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In Veritas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (6.48) |
The market value of In Veritas Medical is measured differently than its book value, which is the value of IVME that is recorded on the company's balance sheet. Investors also form their own opinion of In Veritas' value that differs from its market value or its book value, called intrinsic value, which is In Veritas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In Veritas' market value can be influenced by many factors that don't directly affect In Veritas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In Veritas' value and its price as these two are different measures arrived at by different means. Investors typically determine if In Veritas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In Veritas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.